MCID: PRS042
MIFTS: 43

Prostate Disease

Categories: Endocrine diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Prostate Disease

Summaries for Prostate Disease

MedlinePlus : 42 The prostate is a gland in men. It helps make semen, the fluid that contains sperm. The prostate surrounds the tube that carries urine away from the bladder and out of the body. A young man's prostate is about the size of a walnut. It slowly grows larger with age. If it gets too large, it can cause problems. This is very common after age 50. The older men get, the more likely they are to have prostate trouble. Some common problems are Prostatitis - inflammation, usually caused by bacteria Enlarged prostate (BPH), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night Prostate cancer - a common cancer that responds best to treatment when detected early NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostatic hypertrophy and prostatic adenoma, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Disease is PCA3 (Prostate Cancer Associated 3). The drugs Iodine and Povidone-iodine have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and testes.

Wikipedia : 74 The prostate is an exocrine gland of the male reproductive system in most mammals and some... more...

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 134, show less)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 32.2 SRD5A1 SERPINA3 KLK3 AR
2 prostatic adenoma 32.1 SRD5A1 SERPINA3 KLK3
3 prostatic hyperplasia, benign 32.1 SRD5A1 SERPINA3 KLK3 CDKN2B-AS1 AR
4 prostatitis 31.9 SERPINA3 PCA3 KLK3 AR
5 prostate cancer 31.3 TERC SRD5A1 SERPINA3 SCHLAP1 PTENP1 PRNCR1
6 impotence 31.1 SRD5A1 KLK3 AR
7 suppression of tumorigenicity 12 30.9 SERPINA3 PCA3 KLK3 AR
8 sexual disorder 30.7 SERPINA3 KLK3 AR
9 gynecomastia 30.5 SRD5A1 KLK3 AR
10 alopecia, androgenetic, 1 30.4 SRD5A1 AR
11 renal cell carcinoma, nonpapillary 30.4 SCHLAP1 PTENP1 PCAT1 MALAT1 LINC00963 H19
12 bladder cancer 30.4 TERC SCHLAP1 PCAT1 MEG3 MALAT1 H19
13 androgenic alopecia 10.8 SRD5A1 KLK3 AR
14 prostate adenoid cystic carcinoma 10.8 KLK3 AR
15 prostate leiomyoma 10.8 KLK3 AR
16 bladder urothelial carcinoma 10.8 SRD5A1 MEG3 MALAT1 KLK3 GAS5 AR
17 griscelli syndrome, type 3 10.8 SCHLAP1 PCA3 KLK3
18 prostate calculus 10.8 KLK3 AR
19 ovarian endometrial cancer 10.7 SERPINA3 MALAT1
20 prostatic acinar adenocarcinoma 10.7 KLK3 AR
21 thyroid cancer, nonmedullary, 1 10.7 MEG3 MALAT1 H19
22 astrocytoma 10.7 PCA3 IGF2-AS H19 GAS5 CDKN2B-AS1
23 coronary heart disease 1 10.7 IGF2-AS H19 GAS5 CDKN2B-AS1
24 glioma susceptibility 1 10.7 PCAT1 MEG3 MALAT1 LINC00963 H19 GAS5
25 osteogenic sarcoma 10.7 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
26 glioma 10.7 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1 CBR3-AS1
27 undifferentiated embryonal sarcoma of the liver 10.7 SERPINA3 MALAT1
28 androgen insensitivity, partial 10.7 SRD5A1 AR
29 embryonal sarcoma 10.7 SERPINA3 MALAT1
30 wilms tumor 1 10.7 SERPINA3 MEG3 IGF2-AS H19 AR
31 malignant glioma 10.7 PRNCR1 PCGEM1 MEG3 MALAT1 LINC00963 H19
32 myeloma, multiple 10.7 SERPINA3 PCAT1 MEG3 MALAT1 H19 GAS5
33 cervical cancer 10.7 TERC PCAT1 MEG3 MALAT1 H19 GAS5
34 aortic aneurysm, familial abdominal, 1 10.7 SERPINA3 H19 CDKN2B-AS1
35 endometrial cancer 10.7 TERC SERPINA3 PTENP1 MEG3 KLK3 H19
36 prostate neuroendocrine neoplasm 10.7 KLK3 AR
37 osteoarthritis 10.7 PCGEM1 MEG3 H19 GAS5
38 esophageal cancer 10.7 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
39 prostate stromal sarcoma 10.7 PCA3 KLK3
40 squamous cell carcinoma 10.7 PCAT1 MALAT1 H19 CDKN2B-AS1 CBR3-AS1
41 prostate transitional cell carcinoma 10.7 KLK3 AR
42 nasopharyngeal carcinoma 10.7 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
43 gallbladder cancer 10.7 MEG3 MALAT1 H19 CDKN2B-AS1
44 apocrine adenocarcinoma 10.7 SERPINA3 AR
45 liver cirrhosis 10.7 SERPINA3 MEG3 MALAT1 GAS5
46 thyroid gland cancer 10.7 MALAT1 H19 GAS5 CDKN2B-AS1
47 gastric cancer 10.7 TERC SERPINA3 PTENP1 PRNCR1 PCAT1 MEG3
48 kidney cancer 10.6 MEG3 MALAT1 H19 GAS5
49 hepatocellular carcinoma 10.6 TERC SERPINA3 PTENP1 PCAT1 MEG3 MALAT1
50 pseudovaginal perineoscrotal hypospadias 10.6 SRD5A1 AR
51 male reproductive organ benign neoplasm 10.6 SERPINA3 KLK3
52 vulva squamous cell carcinoma 10.6 MEG3 MALAT1
53 laryngeal squamous cell carcinoma 10.6 MALAT1 H19 CDKN2B-AS1
54 germ cell cancer 10.6 SERPINA3 H19 AR
55 pituitary adenoma 10.5 MEG3 MALAT1 H19
56 leukemia, acute myeloid 10.5 SERPINA3 MEG3 MALAT1 CDKN2B-AS1 AR
57 pancreatic endocrine carcinoma 10.5 SERPINA3 MEG3
58 lung cancer susceptibility 3 10.4 SERPINA3 MEG3 MALAT1 H19 GAS5
59 polycystic ovary syndrome 10.4 SRD5A1 GAS5 AR
60 withdrawal disorder 10.3 KLK3 AR
61 adenoma 10.0
62 adenocarcinoma 10.0
63 spinal cord injury 9.8
64 overgrowth syndrome 9.8
65 vesicoureteral reflux 1 9.7
66 insulin-like growth factor i 9.7
67 body mass index quantitative trait locus 11 9.7
68 body mass index quantitative trait locus 9 9.7
69 body mass index quantitative trait locus 8 9.7
70 body mass index quantitative trait locus 4 9.7
71 body mass index quantitative trait locus 10 9.7
72 body mass index quantitative trait locus 7 9.7
73 body mass index quantitative trait locus 12 9.7
74 body mass index quantitative trait locus 14 9.7
75 body mass index quantitative trait locus 18 9.7
76 pachyonychia congenita 3 9.7
77 body mass index quantitative trait locus 19 9.7
78 body mass index quantitative trait locus 20 9.7
79 pyelonephritis 9.7
80 neurogenic bladder 9.7
81 acute cystitis 9.7
82 cystitis 9.7
83 acromegaly 9.7
84 neurofibromatosis, type ii 9.6
85 alcohol dependence 9.6
86 hypercholesterolemia, familial, 1 9.6
87 migraine with or without aura 1 9.6
88 schistosoma mansoni infection, susceptibility/ 9.6
89 strabismus 9.6
90 thrombophilia due to thrombin defect 9.6
91 myopathy, myosin storage, autosomal recessive 9.6
92 periodontitis, chronic 9.6
93 aging 9.6
94 myocardial infarction 9.6
95 prostate cancer, hereditary, 3 9.6
96 obstructive nephropathy 9.6
97 bone disease 9.6
98 bacterial infectious disease 9.6
99 hydronephrosis 9.6
100 prostatic cyst 9.6
101 disseminated intravascular coagulation 9.6
102 heart disease 9.6
103 infant gynecomastia 9.6
104 conn's syndrome 9.6
105 male infertility 9.6
106 rectal disease 9.6
107 nodular prostate 9.6
108 schistosomiasis 9.6
109 pyuria 9.6
110 papilledema 9.6
111 alcohol use disorder 9.6
112 urethral stricture 9.6
113 hypogonadism 9.6
114 leiomyosarcoma 9.6
115 cerebral palsy 9.6
116 rectum cancer 9.6
117 transitional cell carcinoma 9.6
118 proctitis 9.6
119 lipid metabolism disorder 9.6
120 ischemia 9.6
121 skin disease 9.6
122 urinary tract obstruction 9.6
123 infertility 9.6
124 paraplegia 9.6
125 radiation cystitis 9.6
126 periodontitis 9.6
127 mechanical strabismus 9.6
128 diabetes mellitus 9.6
129 hemorrhoid 9.6
130 48,xyyy 9.6
131 precocious puberty 9.6
132 spasticity 9.6
133 radiation proctitis 9.6
134 pik3ca-related overgrowth syndrome 9.6

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN): (showing 2, show less)


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:


tremor, angina pectoris, equilibration disorder, prostatism

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 70, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 4 7553-56-2 807
2
Povidone-iodine Approved Phase 4 25655-41-8
3
Povidone Approved Phase 4 9003-39-8
4
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
5
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
6 Anti-Infective Agents, Local Phase 4
7 Plasma Substitutes Phase 4
8 cadexomer iodine Phase 4
9 Anti-Infective Agents Phase 4
10 Blood Substitutes Phase 4
11 Fenugreek Phase 4
12 Fenugreek seed meal Phase 4
13
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
14
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
15
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
16 Phosphodiesterase 5 Inhibitors Phase 3
17 Phosphodiesterase Inhibitors Phase 3
18 Vasodilator Agents Phase 3
19 Neurotransmitter Agents Phase 3
20 Adrenergic alpha-Antagonists Phase 3
21 Adrenergic Agents Phase 3
22 Adrenergic Antagonists Phase 3
23 Adrenergic alpha-1 Receptor Antagonists Phase 3
24 Hormone Antagonists Phase 3
25 5-alpha Reductase Inhibitors Phase 3
26
Ethanol Approved Phase 1, Phase 2 64-17-5 702
27
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
28
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181 3911
29
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
30
nivolumab Approved Phase 1, Phase 2 946414-94-4
31
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
32
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
33 Onapristone Investigational Phase 1, Phase 2 96346-61-1
34 Molgramostim Investigational Phase 2 99283-10-0
35 Androgen Antagonists Phase 1, Phase 2
36 Protein Kinase Inhibitors Phase 2
37 Imatinib Mesylate Phase 2 220127-57-1 123596
38 Vaccines Phase 2
39 Albumin-Bound Paclitaxel Phase 2
40 Antineoplastic Agents, Hormonal Phase 2
41 Prolactin Release-Inhibiting Factors Phase 2
42 Immunoglobulins Phase 1, Phase 2
43 Antibodies Phase 1, Phase 2
44 Antibodies, Monoclonal Phase 1, Phase 2
45 Immunoglobulins, Intravenous Phase 1, Phase 2
46 Immunoglobulin G Phase 1, Phase 2
47 Antineoplastic Agents, Immunological Phase 2
48 Tubulin Modulators Phase 2
49 Antimitotic Agents Phase 2
50
Niraparib Approved, Investigational Phase 1 1038915-60-4 24958200
51
Bicalutamide Approved Phase 1 90357-06-5 2375 56069
52 Cola Phase 1
53 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
54 Hops Approved
55
Octreotide Approved, Investigational 83150-76-9 383414 6400441
56
Lactitol Approved, Investigational 585-88-6, 585-86-4 493591
57
Testosterone enanthate Approved 315-37-7 9416
58
Testosterone undecanoate Approved, Investigational 5949-44-0
59
Methyltestosterone Approved 58-18-4 6010
60
Lidocaine Approved, Vet_approved 137-58-6 3676
61
Finasteride Approved 98319-26-7 57363
62
Ciprofloxacin Approved, Investigational 85721-33-1 2764
63 Anesthetics, Local
64 Plasminogen
65 Gastrointestinal Agents
66 Testosterone 17 beta-cypionate
67 Follicle Stimulating Hormone
68 Anabolic Agents
69 Estrogens
70 Anesthetics

Interventional clinical trials:

(showing 54, show less)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
3 Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00827242 Phase 3 Placebo;tadalafil
5 A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
6 A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer Unknown status NCT02049190 Phase 1, Phase 2 onapristone;abiraterone
7 A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy. Unknown status NCT00895466 Phase 1, Phase 2
8 Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
9 An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy Completed NCT01316458 Phase 2 STI571 (Glivec®)
10 Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy Completed NCT03077659 Phase 2 NanoPac®
11 A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy Completed NCT01431391 Phase 2 leuprolide acetate
12 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer Recruiting NCT03543189 Phase 1, Phase 2 Nivolumab;Androgen Deprivation Therapy
13 A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer Terminated NCT00672009 Phase 2 Ixabepilone
14 A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer Terminated NCT02606123 Phase 1, Phase 2 EPI-506
15 A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate Terminated NCT00448097 Phase 2 cetuximab;docetaxel
16 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy Withdrawn NCT03658408 Phase 2 4-aminopyridine;placebo
17 A Randomized Open-label Phase II Study of Oral Dovitinib in Combination With Androgen Deprivation Therapy to Delay the Onset of Castration-resistant Disease in Patients With Metastatic Prostate Cancer Undergoing Primary Androgen Deprivation Therapy Withdrawn NCT02065323 Phase 2 Standard ADT;Dovitinib
18 Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy Completed NCT01307852 Phase 1
19 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
20 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
21 A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruiting NCT04249947 Phase 1 Rimiducid
22 A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer Recruiting NCT04284761 Phase 1
23 An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer Active, not recruiting NCT02578797 Phase 1 Apalutamide
24 Salvage Radiotherapy vs Observation for Castration Resistant Prostate Cancer in Central China Unknown status NCT01590498
25 Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate For Management Of Benign Prostatic Enlargement: An Objective Evaluation Through a Prospective Randomized Trial Unknown status NCT03589196
26 Contrast Enhanced MRI of the Prostate Unknown status NCT02245282
27 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA) Completed NCT01826617
28 Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00941343 Alfuzosin (XATRAL® - SL770499)
29 Intratesticular Hormone Levels in Healthy Young Men Completed NCT00756561
30 Validation of a Semiquantitative Screening Assay for PSA Completed NCT00853710
31 Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer Completed NCT03104907
32 Xbox Kinect Training in Men With Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy Completed NCT01762241
33 Prostatic Artery Embolization for Benign Prostatic Obstruction Completed NCT03099421
34 Prospective Evaluation of the Intraoperative Use of Translumenal Flexible Endoscopes During Combined Flexible and Laparoscopic Foregut and Urologic Surgery Completed NCT00484783
35 Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers Completed NCT02074644
36 Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy Completed NCT00407329
37 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
38 Predictive Value of 3 Months Results on 12 Months Tumor Shrinkage After First-Line Octreotide-LAR Therapy in Patients With Acromegaly Completed NCT00616408 Octreotide-LAR
39 Case Control Study Regarding the Role of Follicle Stimulating Hormone in Chemically Castrated Young Men Completed NCT04134130 Degarelix 120 MG [Firmagon];Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector;Testosterone Undecanoate
40 A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy Completed NCT03192917
41 2013 Annual National Digital Rectal Exam (DRE) Day: Impact on Prostate Health Awareness and Disease Detection Completed NCT01886547
42 MR/TRUS Fusion Guided Prostate Biopsy- An Improved Way To Detect And Quantify Prostate Cancer Recruiting NCT04026763
43 Hypnosis Mask: a New Approach to Management of Pain in Medical Imaging Recruiting NCT03711643
44 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
45 Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease Recruiting NCT04024475
46 Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer Recruiting NCT03344757
47 Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer Active, not recruiting NCT03350529
48 Molecular Studies and Clinical Correlations in Human Prostatic Disease Active, not recruiting NCT00578240
49 Biobank for African American Prostate Cancer Research in Florida Active, not recruiting NCT03232411
50 Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at UCLA Enrolling by invitation NCT03503643
51 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy Not yet recruiting NCT04288427 Finasteride
52 A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis? Terminated NCT02031029
53 Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer Terminated NCT02307552
54 ConfirmMDx Assay is Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy Withdrawn NCT03597386

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Mannitol hexanitrate

Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

40
Prostate, Kidney, Testes, Bone, Spinal Cord, Liver, Smooth Muscle

Publications for Prostate Disease

Articles related to Prostate Disease:

(showing 1525, show less)
# Title Authors PMID Year
1
The impact of tamsulosin on cognition in Alzheimer disease with benign prostate hyperplasia: A study using the Hallym Smart Clinical Data Warehouse. 42
32481389 2020
2
Effect of fire needle therapy on mild-moderate benign prostatic hyperplasia: Protocol for a randomized controlled pilot trial. 42
32481334 2020
3
The effectiveness of electrical stimulation for the management of benign prostatic hyperplasia: A protocol for systematic review and meta analysis. 42
32384438 2020
4
Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells. 61 54
20351196 2010
5
Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. 54 61
19670261 2010
6
Psychological distress and prostate specific antigen levels in men with and without prostate cancer. 61 54
19486654 2009
7
Biomarkers for prostate cancer. 54 61
19507229 2009
8
The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. 54 61
18627423 2009
9
Risk of developing prostate cancer in the future: overview of prognostic biomarkers. 61 54
19375623 2009
10
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. 54 61
19128049 2009
11
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. 54 61
19030020 2009
12
[CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases]. 54 61
19157222 2008
13
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. 54 61
18668524 2008
14
5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. 61 54
18320593 2008
15
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]. 54 61
18686378 2008
16
A preliminary study of the baboon prostate pathophysiology. 54 61
17639509 2007
17
Androgen receptor modulation: lessons learned from beyond the prostate. 61 54
17881894 2007
18
Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients. 61 54
17571482 2007
19
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 54 61
17159365 2007
20
Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. 54 61
17318358 2006
21
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. 61 54
16093978 2005
22
Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride. 61 54
15956333 2005
23
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. 54 61
14532846 2003
24
Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly. 61 54
12962896 2003
25
Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. 61 54
12858359 2003
26
Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters. 61 54
11903683 2001
27
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. 61 54
11720279 2001
28
[Urinary problems and prostate-specific antigen in a Norwegian normal population]. 54 61
11301608 2001
29
Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients. 54 61
11741128 2001
30
Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. 54 61
11326656 2000
31
Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. 54 61
11061535 2000
32
Polyarteritis nodosa mimicking prostatic cancer. 61 54
11036851 2000
33
[Screening for prostatic diseases in one-day total health check-up by using prostate specific antigen, international prostate symptom score and QOL index]. 61 54
11107529 2000
34
Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer. 54 61
10750886 2000
35
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. 54 61
10632336 1999
36
Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein. 61 54
10510889 1999
37
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. 61 54
9730460 1998
38
Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer. 54 61
9352130 1997
39
PSA divergence. A new parameter for the accurate longitudinal assessment of prostatic disease. 54 61
8638528 1996
40
[Influence of age on serum prostate specific antigen concentration]. 54 61
9594181 1996
41
Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease. 54 61
8977078 1996
42
Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. 61 54
8750649 1995
43
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. 54 61
7479385 1995
44
Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma. 61 54
8725043 1995
45
Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. 61 54
7521173 1994
46
[Variability of values of prostate-specific antigen determined with 6 methods]. 61 54
7514278 1994
47
Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen. 54 61
7531895 1994
48
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]. 54 61
7685140 1993
49
[Significance of prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in the urine. First report: the measurement of PAP, gamma-Sm and PA in the urine of patients with prostatic diseases]. 61 54
1721770 1991
50
[A mass screening of the prostatic diseases and serum prostate specific antigen]. 54 61
1720276 1991
51
Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. 54 61
1697014 1990
52
[The histological expression of prostate-specific antigen and its clinical significance in patients with prostate cancer]. 61 54
1698232 1990
53
Correlation between prostate-specific antigen and prostate volume, evaluated by transrectal ultrasonography: usefulness in diagnosis of prostate cancer. 54 61
1699766 1990
54
Mischievous malakoplakia: A potential pitfall of mpMRI of the prostate? 61
32373473 2020
55
Propagation of human prostate tissue from induced pluripotent stem cells. 61
32170918 2020
56
The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer. 61
32525077 2020
57
Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities. 61
31811242 2020
58
Synthesis, characterization, biological activities and molecular docking of Epilobium parviflorum aqueous extract loaded chitosan nanoparticles. 61
32544580 2020
59
Three-Dimensional Convolutional Neural Network for Prostate MRI Segmentation and Comparison of Prostate Volume Measurements by Use of Artificial Neural Network and Ellipsoid Formula. 61
32208009 2020
60
Telomere DNA damage signaling regulates prostate cancer tumorigenesis. 61
32467172 2020
61
Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. 61
31977495 2020
62
Spatiotemporal Proteomics Reveals the Molecular Consequences of Hormone Treatment in a Mouse Model of Lower Urinary Tract Dysfunction. 61
32108482 2020
63
Comparison of Transabdominal and Transrectal Ultrasound for Sizing of the Prostate. 61
32333985 2020
64
[Urological research in Germany : A retrospective, longitudinal observational study]. 61
32347325 2020
65
[Effects of dynamic contrast enhancement on diffusion weighted imaging score of 3 in prostate imaging reporting and data system version 2 of peripheral zone]. 61
32294857 2020
66
Findings of Gynecomastia That Developed in Follow-up Secondary to Bicalutamide Treatment on Bone Scan. 61
32368880 2020
67
Development of Ureteral Stenosis/Obstruction in Kidney Transplant. 61
32061424 2020
68
Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml-1). 61
31169140 2020
69
Insilico and In Vitro Study: COX-2 Inhibition by Ethanol Extract of Dayak Onion Bulb (Eleutherine americana Merr) as Treatment Innovation of Benign Prostatic Hyperplasia (BPH). 61
32129166 2020
70
A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy. 61
32139288 2020
71
Longitudinal changes in prostate volume in a community-based cohort study of middle-aged and elderly men in rural China. 61
31539457 2020
72
Increased estrogen levels altered microRNA expression in prostate and plasma of rats dosed with sex hormones. 61
32103627 2020
73
Prostate Benign Diseases. 61
32015291 2020
74
Late-onset hypogonadism: Prostate safety. 61
32056383 2020
75
Ejaculation Effect on Canine Prostatic Specific Esterase Serum Concentration. 61
32120886 2020
76
[Novelties in Urology 2019]. 61
31961092 2020
77
Multimodal feature learning and fusion on B-mode ultrasonography and sonoelastography using point-wise gated deep networks for prostate cancer diagnosis. 61
31743102 2020
78
Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine. 61
32284825 2020
79
Expression of miR-148b-3p is correlated with overexpression of biomarkers in prostate cancer. 61
32154827 2020
80
Association of Angiotensin I Converting Enzyme Insertion/287 bp Deletion Polymorphisms and Proliferative Prostatic Diseases among Lebanese Men. 61
32089890 2020
81
A review of microscopy-based evidence for the association of Propionibacterium acnes biofilms in degenerative disc disease and other diseased human tissue. 61
31359216 2019
82
Prospective evaluation of urinary steroids and prostate carcinoma-induced deviation: preliminary results. 61
31833333 2019
83
A case report of primary prostate intravascular large B cell lymphoma presenting as prostatic hyperplasia. 61
31852153 2019
84
PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. 61
31530439 2019
85
[Improvement of performance of semen culture in infertile men undergone to diagnostic evaluation]. 61
32003163 2019
86
Angiotensin receptor autoantibodies as exposures that modify disease progression: Cross sectional, longitudinal and in vitro studies of prostate cancer. 61
31930191 2019
87
Glycosylation products in prostate diseases. 61
31400314 2019
88
Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men. 61
31454437 2019
89
[Detection of BRAF mutation in canine prostatic diseases]. 61
31627222 2019
90
Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk. 61
31376187 2019
91
Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population. 61
31626149 2019
92
Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients. 61
31633263 2019
93
Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. 61
31577095 2019
94
Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation. 61
31271729 2019
95
Evaluation of canine prostate volume in calculated tomographic images - comparison of two assessment methods. 61
31640698 2019
96
Design of a Clinical Decision Support System for Predicting Erectile Dysfunction in Men Using NHIRD Dataset. 61
30369456 2019
97
Impact of total PSA and percent free PSA in the differentiation of prostate disease: a retrospective comparative study implicating neoplastic and non-neoplastic entities. 61
31786882 2019
98
Transcription regulators are transiently expressed during the prostate gland adaptation to the hypoandrogenic environment. 61
30912572 2019
99
Caveolins; An Assailant or An Ally of Various Cellular Disorders. 61
30776841 2019
100
A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapies. 61
31469635 2019
101
Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation. 61
30683762 2019
102
Current Knowledge of the Potential Links between Inflammation and Prostate Cancer. 61
31390729 2019
103
Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells. 61
30618413 2019
104
A temporal and spatial map of axons in developing mouse prostate. 61
30976911 2019
105
Anti-androgenic therapy with finasteride in patients with chronic heart failure - a retrospective propensity score based analysis. 61
31300720 2019
106
Treatment of Prostate Disease and Cognitive Problems. 61
31260607 2019
107
Clinical approach to prostatic diseases in the dog. 61
30974484 2019
108
The prevalence and risk factors of prostatic calculi in Han Chinese: a cross-sectional study based on health examinations. 61
31156012 2019
109
Prostate-Specific Antigen Within the Reference Range, Subclinical Coronary Atherosclerosis, and Cardiovascular Mortality. 61
30885050 2019
110
Prostate enlargement and altered urinary function are part of the aging process. 61
31085797 2019
111
Second-harmonic generation microscopy analysis reveals proteoglycan decorin is necessary for proper collagen organization in prostate. 61
31148435 2019
112
Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients with and without Prostate Cancer. 61
30676475 2019
113
Incidence of prostate cancer among patients with prostate-related urinary symptoms: A single institution series in 10 years. 61
31040596 2019
114
Sperm epimutation biomarkers of obesity and pathologies following DDT induced epigenetic transgenerational inheritance of disease. 61
31186947 2019
115
Assessment of Glyphosate Induced Epigenetic Transgenerational Inheritance of Pathologies and Sperm Epimutations: Generational Toxicology. 61
31011160 2019
116
Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer. 61
30867737 2019
117
Sociodemographic factors that affect the real treatment rate among patients diagnosed with benign prostatic hyperplasia. 61
30857454 2019
118
Prostate cancer and prostatic diseases Best of China, 2018. 61
30518869 2019
119
Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats. 61
31143671 2019
120
Direct mechanical characterization of prostate tissue-a systematic review. 61
30225866 2019
121
A folic acid-enriched diet attenuates prostate involution in response to androgen deprivation. 61
30298636 2019
122
Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men. 61
30840795 2019
123
Environmental Toxicant Induced Epigenetic Transgenerational Inheritance of Prostate Pathology and Stromal-Epithelial Cell Epigenome and Transcriptome Alterations: Ancestral Origins of Prostate Disease. 61
30778168 2019
124
Validation of canine prostate volumetric measurements in computed tomography determined by the slice addition technique using the Amira program. 61
30717756 2019
125
Magnetic resonance imaging-guided transperineal prostate biopsy. 61
30964117 2019
126
Association between oral pathogens and prostate cancer: building the relationship. 61
30906801 2019
127
MRI-guided, transrectal, intraprostatic steam application as potential focal therapeutic modality for prostatic diseases in a large animal translational model: A feasibility follow-up study. 61
31869376 2019
128
Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue. 61
30591067 2018
129
Oxidative damage in patients with benign prostatic hyperplasia and prostate cancer co-exposed to phthalates and to trace elements. 61
30808488 2018
130
Role of PPAR-α agonist fenofibrate in the treatment of induced benign prostatic hyperplasia with dysplastic changes in rats. 61
29862557 2018
131
A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra. 61
30566875 2018
132
Advances in Prostatic Diagnostics in Dogs: The Role of Canine Prostatic Specific Esterase in the Early Diagnosis of Prostatic Disorders. 61
30502858 2018
133
PITUITARY EVALUATION IN PATIENTS WITH LOW PROSTATE-SPECIFIC ANTIGEN. 61
30289304 2018
134
The distribution of BCG prostatitis: A clue for pathogenetic processes? 61
29987889 2018
135
Accuracy of ultrasonography and fine-needle aspiration cytology in the diagnosis of prostate diseases in dogs. 61
30474330 2018
136
Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. 61
30374274 2018
137
CPSE determination and detection of canine prostatic diseases: The importance of a specific diagnosis. 61
29956380 2018
138
[Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians]. 61
29574008 2018
139
[Expressions of microRNAs in prostatic diseases: Advances in studies]. 61
32212462 2018
140
Lycium chinense Mill improves hypogonadism via anti-oxidative stress and anti-apoptotic effect in old aged rat model. 61
30269620 2018
141
Anti-androgenic therapy with finasteride improves cardiac function, attenuates remodeling and reverts pathologic gene-expression after myocardial infarction in mice. 61
30118791 2018
142
Myeloperoxidase and Prostate volume: A preliminary study. 61
30042072 2018
143
[Prostate artery embolisation is a new treatment for prostate disease]. 61
30084348 2018
144
Maternal protein malnutrition: effects on prostate development and adult disease. 61
29582717 2018
145
A pilot study in intraparenchymal therapy delivery in the prostate: a comparison of delivery with a porous needle vs standard needle. 61
30055610 2018
146
Prostatic Calculi: Do They Matter? 61
29157875 2018
147
Canine Prostate Disease. 61
29933768 2018
148
Diagnostic Performance and Interobserver Consistency of the Prostate Imaging Reporting and Data System Version 2: A Study on Six Prostate Radiologists with Different Experiences from Half a Year to 17 Years. 61
29998885 2018
149
Operations for Suspected Neoplasms in a Resource-Limited Setting: Experience and Challenges in the Eastern Democratic of Congo. 61
29290072 2018
150
Identification and preliminary study of immunogens involved in autoimmune prostatitis in human males. 61
29947032 2018
151
Monocenter Experience with 532 Nm-Laser Photoselective-Vaporization of the Prostate by GreenLight XPS™ Laser: Is It Really an Endourological Joker Card? 61
29791696 2018
152
Unilateral upper extremity lymphedema in metastatic prostate cancer. 61
29881554 2018
153
[Analysis of the prevalence and related risk factors of prostate diseases in traffic policemen]. 61
30248739 2018
154
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. 61
29335762 2018
155
Macrophage Cytokines Enhance Cell Proliferation of Normal Prostate Epithelial Cells through Activation of ERK and Akt. 61
29769604 2018
156
The malignancy index in plasma samples as a prostate cancer biomarker. 61
29906406 2018
157
An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example. 61
29408166 2018
158
Homeostasis: apoptosis and cell cycle in normal and pathological prostate. 61
29730957 2018
159
20 years-A retrospective of prostate cancer and prostatic diseases. 61
29259294 2018
160
Canine prostate specific esterase (CPSE) as an useful biomarker in preventive screening programme of canine prostate: CPSE threshold value assessment and its correlation with ultrasonographic prostatic abnormalities in asymptomatic dogs. 61
29164718 2018
161
Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study. 61
29523809 2018
162
Setting up a service for men with benign prostate disease. 61
29561636 2018
163
Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease? 61
29117997 2018
164
Association between male pattern baldness and prostate disease: A meta-analysis. 61
29054497 2018
165
Candidate diagnostic miRNAs that can detect cancer in prostate biopsy. 61
29226351 2018
166
Is oxidative stress measured by thiol/disulphide homeostasis status associated with prostate adenocarcinoma? 61
30135630 2018
167
Central Serous Chorioretinopathy: Clinical Characteristics Associated with Visual Outcomes. 61
30067427 2018
168
Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy. 61
30050933 2018
169
Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels. 61
29518100 2018
170
Preputial mucosal graft for urethral repair. 61
28836924 2018
171
Vinclozolin induced epigenetic transgenerational inheritance of pathologies and sperm epimutation biomarkers for specific diseases. 61
30157260 2018
172
Study on the inhibition of Mfn1 by plant-derived miR5338 mediating the treatment of BPH with rape bee pollen. 61
29382326 2018
173
Extraction, purification of prostate-specific antigen (PSA), and establishment of radioimmunoassay system as a diagnostic tool for prostate disorders. 61
29144195 2018
174
The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition. 61
29372682 2017
175
Dynamic instrumented palpation - a new method for soft tissue quality assessment: application to prostate disease diagnosis. 61
28965477 2017
176
Re: Evolution of Primary Care Referrals to Urology. Impact of a Protocol on Prostate Disease and Continuing Education. 61
29144897 2017
177
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. 61
28819703 2017
178
Identification of CpG Sites of SERPINA5 Promoter with Opposite Methylation Patterns in Benign and Malignant Prostate Cells. 61
29187436 2017
179
Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. 61
28940538 2017
180
Elevated hardness of peripheral gland on real-time elastography is an independent marker for high-risk prostate cancers. 61
28836176 2017
181
[Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer]. 61
29325321 2017
182
Oxidative stress and prostatic diseases. 61
29181163 2017
183
Risk factors for contralateral inguinal hernia repair after unilateral inguinal hernia repair in male adult patients: analysis from a nationwide population based cohort study. 61
29157231 2017
184
Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases. 61
28699177 2017
185
Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study. 61
29211357 2017
186
Determinants of Behavioral Intentions to Screen for Prostate Cancer in Omani Men. 61
28966965 2017
187
Urinary-exosomal miR-2909: A novel pathognomonic trait of prostate cancer severity. 61
28764970 2017
188
Evaluation of the Efficacy of Post Prostatic Massage Urine Cytology in Diagnosis of Various Prostatic Lesions with Cytohistological and Clinical Correlation. 61
29118477 2017
189
Traditional medicines and alternative practice in the management of prostate diseases in southern Ghana. 61
29622824 2017
190
Association between systemic inflammation and serum prostate-specific antigen in a healthy Korean population. 61
28861299 2017
191
Simultaneous Detection of Oral Pathogens in Subgingival Plaque and Prostatic Fluid of Men With Periodontal and Prostatic Diseases. 61
28548883 2017
192
MR measurement of luminal water in prostate gland: Quantitative correlation between MRI and histology. 61
28130866 2017
193
Looking to the metabolic landscapes for prostate health monitoring. 61
28828350 2017
194
Role of connexin 43 in cadmium-induced proliferation of human prostate epithelial cells. 61
28176351 2017
195
[Gene regulation of prostaglandin synthase and prostate diseases]. 61
29723463 2017
196
Crocus sativus, Serenoa repens and Pinus massoniana extracts modulate inflammatory response in isolated rat prostate challenged with LPS. 61
28889734 2017
197
The potential of organoids in urological cancer research. 61
28534535 2017
198
Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. 61
28472278 2017
199
Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis. 61
28326819 2017
200
Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization. 61
28530520 2017
201
Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer. 61
28187264 2017
202
Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders. 61
28191652 2017
203
High-Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach. 61
28190704 2017
204
Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy. 61
28139757 2017
205
Epithelial-mesenchymal transition in prostate cancer: an overview. 61
28430640 2017
206
Selective anti-proliferative activities of Carica papaya leaf juice extracts against prostate cancer. 61
28249253 2017
207
A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy. 61
28110975 2017
208
Computed tomography: a beneficial diagnostic tool for the evaluation of the canine prostate? 61
28482833 2017
209
Over-Expression of Activin-βC Is Associated with Murine and Human Prostate Disease. 61
28116672 2017
210
Prenatal and pubertal testosterone exposure imprint permanent modifications in the prostate that predispose to the development of lesions in old Mongolian gerbils. 61
26780870 2017
211
Environmental factors, epigenetics, and developmental origin of reproductive disorders. 61
27421580 2017
212
The role of prostatic inflammation in the development and progression of benign and malignant diseases. 61
27906778 2017
213
Optimizing structural and mechanical properties of cryogel scaffolds for use in prostate cancer cell culturing. 61
27987733 2017
214
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. 61
28143503 2017
215
Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions. 61
27931798 2017
216
Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. 61
28289563 2017
217
Knowledge, attitudes and screening practices regarding prostatic diseases among men older than 40 years: a population-based study in Southwest Nigeria. 61
28904679 2017
218
Parental High-Fat Diet Promotes Inflammatory and Senescence-Related Changes in Prostate. 61
28261375 2017
219
68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review. 61
28217012 2017
220
Fatigue, depression, and quality of life in patients with prostatic diseases. 61
28461987 2017
221
Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts. 61
27593477 2017
222
Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease. 61
27845125 2016
223
Inducible expression of cancer-testis antigens in human prostate cancer. 61
27769045 2016
224
Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. 61
27749016 2016
225
Human Papilloma Virus Detection by INNOLiPA HPV in Prostate Tissue from Men of Northeast Mexico 61
28030912 2016
226
Contribution of Caudal Müllerian Duct Mesenchyme to Prostate Development. 61
27595922 2016
227
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. 61
27683107 2016
228
Enhanced detection sensitivity of prostate-specific antigen via PSA-conjugated gold nanoparticles based on localized surface plasmon resonance: GNP-coated anti-PSA/LSPR as a novel approach for the identification of prostate anomalies. 61
27740614 2016
229
Immediate Continence Rates in RALRP: A Comparison of Three Techniques. 61
27777500 2016
230
Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study. 61
27152882 2016
231
Unfoldomics of prostate cancer: on the abundance and roles of intrinsically disordered proteins in prostate cancer. 61
27453073 2016
232
Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report. 61
29320623 2016
233
Emerging medication for the treatment of male hypogonadism. 61
27552127 2016
234
Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. 61
27581270 2016
235
ERG expression in prostate cancer: biological relevance and clinical implication. 61
26711283 2016
236
Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer. 61
26976206 2016
237
Erratum: Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. 61
27436144 2016
238
Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone. 61
27172434 2016
239
Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations. 61
27759820 2016
240
The role of the prostate in male fertility, health and disease. 61
27245504 2016
241
DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. 61
26987799 2016
242
Glycosylation status of serum immunoglobulin G in patients with prostate diseases. 61
26880719 2016
243
Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. 61
27170414 2016
244
An observational Study of the Association between Androgenetic Alopecia and Size of the Prostate. 61
27601858 2016
245
The impact of obesity towards prostate diseases. 61
27014656 2016
246
A retrospective study of canine prostatic diseases from 2002 to 2009 at the Alfort Veterinary College in France. 61
26613854 2016
247
Associations between maternal phenolic exposure and cord sex hormones in male newborns. 61
26724800 2016
248
Uric acid: a modulator of prostate cells and activin sensitivity. 61
26910779 2016
249
Prevalence of erectile dysfunction in patients consulting urological clinics: multi-centric survey in the algerian west. 61
27532528 2016
250
The mouse prostate: a basic anatomical and histological guideline. 61
26773172 2016
251
An Analytical Study of Prostate-Specific Antigen Dynamics. 61
27956935 2016
252
[What role does botulinum toxin play in the treatment of benign prostatic hyperplasia?] 61
28154664 2016
253
Prostate Cancer, High Cortisol Levels and Complex Hormonal Interaction. 61
27509946 2016
254
Locus-specific gene repositioning in prostate cancer. 61
26564800 2016
255
Doxazosin Stimulates Galectin-3 Expression and Collagen Synthesis in HL-1 Cardiomyocytes Independent of Protein Kinase C Pathway. 61
28066244 2016
256
Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. 61
26296672 2016
257
Histochemical evaluation of postnatal lectin-binding sites in the mouse prostate. 61
27319301 2016
258
The Effect of Testosterone on Men With Andropause. 61
26756004 2015
259
New transcription factors involved with postnatal ventral prostate gland development in male Wistar rats during the first week. 61
26549646 2015
260
Contrast-enhanced ultrasonographic characteristics of the diseased canine prostate gland. 61
26277703 2015
261
Prostatic diseases under focus in a university hospital in Eastern Saudi Arabia. A 15-year experience. 61
26593165 2015
262
Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. 61
26497345 2015
263
Genistein reduces the noxious effects of in utero bisphenol A exposure on the rat prostate gland at weaning and in adulthood. 61
26260748 2015
264
Multicentre study of 18F-FDG-PET/CT prostate incidental uptake. 61
26153112 2015
265
Prenatal exposure to testosterone masculinises the female gerbil and promotes the development of lesions in the prostate (Skene's gland). 61
25483231 2015
266
Testosterone Replacement Therapy on the Natural History of Prostate Disease. 61
26077355 2015
267
Epithelial and stromal alterations in prostate after cypermethrin administration in adult albino rats (histological and biochemical study). 61
25987297 2015
268
Ethnicity and Prostate Cancer in Southern Nigeria: A Preliminary Report. 61
26425060 2015
269
Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy. 61
25845467 2015
270
[PATHOGENETIC TREATMENT OF CHRONIC NONBACTERIAL PROSTATITIS COMPLICATED BY SPERM DISORDERS]. 61
26665768 2015
271
Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. 61
26171936 2015
272
Subspecialty training in andrology. 61
26048154 2015
273
Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review. 61
25523493 2015
274
Evolution of primary care referrals to urology. Impact of a protocol on prostate disease and continuing education. 61
25554605 2015
275
Relationship Between Second to Fourth Digit Ratios and Benign Prostatic Hyperplasia in Aging Men. 61
26155515 2015
276
Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA level. 61
29264129 2015
277
Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. 61
25323935 2015
278
Knowledge and attitude of the population toward cancer prostate Riyadh, Saudi Arabia. 61
25837827 2015
279
Immunoelectron microscope localization of androgen receptors and proliferating cell nuclear antigen in the epithelial cells of albino rat ventral prostate. 61
30023185 2015
280
Impact of comorbidity on 6-month hospital readmission and mortality after hip fracture surgery. 61
25627481 2015
281
Assessing the utilization of functional imaging in multiparametric prostate MRI in routine clinical practice. 61
25578231 2015
282
Antiandrogenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction. 61
25632043 2015
283
DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. 61
25700986 2015
284
Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene. 61
25700984 2015
285
Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. 61
25432062 2015
286
5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. 61
25239636 2015
287
Morphology of treatment-related changes in the prostate and prostatic cancer. 61
26072634 2015
288
Enhancing Knowledge, Beliefs, and Intention to Screen for Prostate Cancer via Different Health Educational Interventions: a Literature Review. 61
26514484 2015
289
Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL. 61
26225663 2015
290
Stem-cell-based therapy in the field of urology: a review of stem cell basic science, clinical applications and future directions in the treatment of various sexual and urinary conditions. 61
26243575 2015
291
Expression of some selected cytokeratins and Ki67 protein in prostatic tumor: can these be used as tumor markers. 61
26090004 2015
292
Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases. 61
26417612 2015
293
Overexpression of periostin in stroma positively associated with aggressive prostate cancer. 61
25781169 2015
294
Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer. 61
24665929 2015
295
The effect of chronic prostatitis on zinc concentration of prostatic fluid and seminal plasma: a systematic review and meta-analysis. 61
26173049 2015
296
Oxidative stress in benign prostatic hyperplasia: a systematic review. 61
25503259 2015
297
Association of Alcohol Consumption with Markers of Prostate Health and Reproductive Hormone Profiles: A Multi-Center Study of 4,535 Men in China. 61
26559058 2015
298
The influence of primary care quality on hospital admissions for people with dementia in England: a regression analysis. 61
25816231 2015
299
Cell kinetic studies fail to identify sequentially proliferating progenitors as the major source of epithelial renewal in the adult murine prostate. 61
26024527 2015
300
MMP-2 and MMP-9 activities and TIMP-1 and TIMP-2 expression in the prostatic tissue of two ethanol-preferring rat models. 61
26258010 2015
301
In vitro modeling of the prostate cancer microenvironment. 61
24816064 2014
302
The simultaneous detection of free and total prostate antigen in serum samples with high sensitivity and specificity by using the dual-channel surface plasmon resonance. 61
25016334 2014
303
Xenotransplantation models to study the effects of toxicants on human fetal tissues. 61
25477288 2014
304
Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. 61
25035153 2014
305
Hospital acquired blood stream infection as an adverse outcome for patients admitted to hospital with other principle diagnosis. 61
25538530 2014
306
The anti-proliferative effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage. 61
25372501 2014
307
Prostate cancer immunotherapy: beyond immunity to curability. 61
25367978 2014
308
Prostate cancer. Foreword. 61
25367319 2014
309
Impact of cosmetic result on selection of surgical treatment in patients with localized prostate cancer. 61
25516703 2014
310
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. 61
26594314 2014
311
Prevalence of Trichomonas vaginalis by PCR in men attending a primary care urology clinic in South Korea. 61
25352707 2014
312
The relationship between solar UV exposure, serum vitamin D levels and serum prostate-specific antigen levels, in men from New South Wales, Australia: the CHAMP study. 61
24190367 2014
313
Management of lower urinary retention in a limited resource setting. 61
25489197 2014
314
Male sexual function can be maintained without aromatization: randomized placebo-controlled trial of dihydrotestosterone (DHT) in healthy, older men for 24 months. 61
24751323 2014
315
Feasibility of diffusional kurtosis tensor imaging in prostate MRI for the assessment of prostate cancer: preliminary results. 61
24848289 2014
316
Late onset hypogonadism of men is not equivalent to the menopause. 61
25042874 2014
317
Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. 61
24830688 2014
318
[5ARI and PSA: therapeutic aspects]. 61
24744217 2014
319
[Benign prostatic hypertrophy and prostate cancer]. 61
25373266 2014
320
Assessment of association between common variants at 17q12 and prostate cancer risk-evidence from Serbian population and meta--analysis. 61
24422606 2014
321
Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. 61
24929891 2014
322
PATTERN OF OVERACTIVE BLADDER IN SOUTHEAST NIGERIA. 61
26457269 2014
323
Metabolic syndrome and diabetes for the urologist. 61
25243043 2014
324
Factors influencing the acceptance of transrectal ultrasound-guided prostate biopsies. 61
25045444 2014
325
Diagnosis of common prostatic conditions in dogs: an update. 61
24947861 2014
326
Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update. 61
24947855 2014
327
Promoter Polymorphism (rs12770170, -184C/T) of Microseminoprotein, Beta as a Risk Factor for Benign Prostatic Hyperplasia in Korean Population. 61
24987558 2014
328
Identifying risk factors for surgical site complications after laparoscopic ventral hernia repair: evaluation of the Ventral Hernia Working Group grading system. 61
24773169 2014
329
Chronic pelvic pain: comorbidity between chronic musculoskeletal pain and vulvodynia. 61
24938200 2014
330
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. 61
24979481 2014
331
Overdetection in screening for prostate cancer. 61
24670870 2014
332
Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. 61
24500928 2014
333
[Prostate stem cells: an update]. 61
24908740 2014
334
Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. 61
24435840 2014
335
BPH and prostate cancer risk. 61
24744523 2014
336
[In Process Citation]. 61
24670603 2014
337
Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. 61
24338683 2014
338
The prevalence of lower urinary tract symptoms in a Chinese population, and the correlation with uroflowmetry and disease perception. 61
24136186 2014
339
Androgens and prostate disease. 61
24407178 2014
340
Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications. 61
24457841 2014
341
Primary non-Hodgkin follicular lymphoma of the prostate: A case report. 61
26328148 2014
342
Recurrence and pseudorecurrence after laparoscopic ventral hernia repair: predictors and patient-focused outcomes. 61
24480213 2014
343
Lectin-binding sites in epithelial cells of the mouse prostate gland. 61
26004072 2014
344
New and experimental techniques in the treatment of benign prostatic diseases. 61
25782231 2014
345
Lycopene for the prevention and treatment of prostate disease. 61
24531784 2014
346
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient. 61
24132461 2014
347
MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases. 61
24115268 2014
348
New serum biomarkers for prostate cancer diagnosis. 61
25593898 2014
349
Knowledge and Perception of Nigerian Men 40 years and above Regarding Prostate Cancer. 61
26587514 2014
350
Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. 61
25606581 2014
351
The continuous evolution of the Greenlight laser; the XPS generator and the MoXy laser fiber, expanding the indications for photoselective vaporization of the prostate. 61
23992242 2014
352
Nonsteroidal anti-inflammatory drugs and prostatic diseases. 61
24900965 2014
353
Maturation of the developing human fetal prostate in a rodent xenograft model. 61
24038131 2013
354
Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome. 61
24001894 2013
355
Role of adhesion molecules and proliferation hyperplasic, pre neoplastic and neoplastic lesions in canine prostate. 61
24511741 2013
356
Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer. 61
23421929 2013
357
Health-related quality of life for men with prostate cancer--an evaluation of outcomes 12-24 months after treatment. 61
22608541 2013
358
Ancestral dichlorodiphenyltrichloroethane (DDT) exposure promotes epigenetic transgenerational inheritance of obesity. 61
24228800 2013
359
Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer. 61
24403231 2013
360
Serum PSA as a predictor of testosterone deficiency. 61
23859334 2013
361
Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscesses. 61
23689049 2013
362
Normal canine prostate gland: repeatability, reproducibility, observer-dependent variability of ultrasonographic measurements of the prostate in healthy intact beagles. 61
23293870 2013
363
AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. 61
23864729 2013
364
Hospitalization decreases serum prostate-specific antigen values compared with outpatient values in patients with benign prostatic diseases. 61
24044092 2013
365
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. 61
23688836 2013
366
The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues. 61
23607319 2013
367
Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat. 61
21872499 2013
368
An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. 61
23675780 2013
369
Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression. 61
23872639 2013
370
Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group. 61
23806388 2013
371
A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. 61
23389852 2013
372
Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001-2008. 61
23713595 2013
373
Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia. 61
23836950 2013
374
Formation of human prostate epithelium using tissue recombination of rodent urogenital sinus mesenchyme and human stem cells. 61
23852031 2013
375
Re: Involvement of estrogen receptors in prostatic diseases. 61
23663624 2013
376
Prostatic stromal neoplasms: differential diagnosis of cystic and solid prostatic and periprostatic masses. 61
23701087 2013
377
Laparoscopic ventral hernia repair: primary versus secondary hernias. 61
22795342 2013
378
The male reproductive system - An overview of common problems. 61
23781524 2013
379
Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study. 61
23641775 2013
380
Effect of microbubble-enhanced ultrasound on prostate permeability: a potential therapeutic method for prostate disease. 61
23414693 2013
381
Current status of 5α-reductase inhibitors in prostate disease management. 61
23614056 2013
382
Autopsy study of prostatic weight and lesions in LUTH: a 12 month prospective study. 61
24579501 2013
383
Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. 61
23154423 2013
384
Recent advances in prostate development and links to prostatic diseases. 61
23335485 2013
385
Effects of metoclopramide on mRNA levels of steroid 5α-reductase isozymes in prostate of adult rats. 61
22806172 2013
386
[Research on serum prostate-specific antigen measurement by characteristic spectral imaging method]. 61
23705449 2013
387
Androgens promote prostate cancer cell growth through induction of autophagy. 61
23250485 2013
388
Future prospects in the diagnosis and management of localized prostate cancer. 61
24163619 2013
389
Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia. 61
23432584 2013
390
[Urology. Trends in prostatic diseases in 2012]. 61
23409657 2013
391
Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. 61
23359474 2013
392
Prostate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species production. 61
25374899 2013
393
Lack of liver X receptors leads to cell proliferation in a model of mouse dorsal prostate epithelial cell. 61
23554947 2013
394
Susceptibility weighted imaging: a new tool in the diagnosis of prostate cancer and detection of prostatic calcification. 61
23308170 2013
395
Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer. 61
24223413 2013
396
Prostate embryonal rhabdomyosarcoma in adults: Case report and review of literature. 61
24416569 2013
397
Male reproductive health disorders among Aboriginal and Torres Strait Islander men: a hidden problem? 61
23330768 2013
398
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications. 61
23690774 2013
399
Clinico-pathological Correlation of Digital Rectal Examination Findings Amongst Nigerian Men with Prostatic Diseases: A Prospective Study of 236 Cases. 61
24027415 2013
400
Bisphenol A exposure during adulthood alters expression of aromatase and 5α-reductase isozymes in rat prostate. 61
23405234 2013
401
Expression of steroid 5α-reductase isozymes in prostate of adult rats after environmental stress. 61
23122426 2013
402
Resveratrol in prostate diseases - a short review. 61
24579014 2013
403
β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. 61
23300485 2013
404
[Biopsy findings of low-risk prostate disease: are they real? Single centre experience]. 61
22729603 2012
405
Prostate Cancer and Prostatic Diseases (2012) 15, 313. 61
23147068 2012
406
Retinoic acid receptor β2 (RARβ2): nonivasive biomarker for distinguishing malignant versus benign prostate lesions from bodily fluids. 61
23294958 2012
407
Prenatal testosterone exposure as a model for the study of endocrine-disrupting chemicals on the gerbil prostate. 61
23239441 2012
408
[Evolution of prostatic surgical interventions: analysis of French national coding database]. 61
22999118 2012
409
Profile of NF-κBp(65/NFκBp50) among prostate specific antigen sera levels in prostatic pathologies. 61
21889270 2012
410
Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men. 61
22648746 2012
411
Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue. 61
23009291 2012
412
[Drug penetrability and etiologic diagnosis and treatment of prostatitis in men]. 61
23193661 2012
413
Role of 5α-reductase inhibitors in benign prostatic diseases. 61
22333687 2012
414
Epigenetic markers of prostate cancer in plasma circulating DNA. 61
22619380 2012
415
Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. 61
22659250 2012
416
PPARγ isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation. 61
22874998 2012
417
Senescence and steroid hormone receptor reactivities in accessory sex glands of elderly rats (Sprague-Dawley) following exogenous hormonal therapy. 61
22541803 2012
418
[Neurophysiologic evaluation of patients with chronic prostatitis (III B chronic pain syndrome)]. 61
23116021 2012
419
Opioid-induced androgen deficiency (OPIAD). 61
22786453 2012
420
DNA repair system and prostate cancer progression: the role of NBS1 polymorphism (rs1805794). 61
22413803 2012
421
[Sexual dysfunctions linked with prostatic diseases]. 61
22770495 2012
422
Involvement of estrogen receptors in prostatic diseases. 61
22375605 2012
423
SU-E-T-615: Quantifying the Benefit of Adaptive Fractionation. 61
28517062 2012
424
Editorial comment to involvement of estrogen receptors in prostatic diseases. 61
22621219 2012
425
Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle. 61
22425049 2012
426
[The relationship between oxidative stress and obesity in prostate disease]. 61
22522464 2012
427
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling. 61
22233684 2012
428
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. 61
22339264 2012
429
Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. 61
22284307 2012
430
Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. 61
22209970 2012
431
The correlation between metabolic syndrome and prostatic diseases. 61
22119157 2012
432
Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. 61
22247499 2012
433
Alterations of global histone H4K20 methylation during prostate carcinogenesis. 61
22413846 2012
434
Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men. 61
22093190 2012
435
Dietary patterns and prostatic diseases. 61
22201864 2012
436
Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. 61
21992222 2012
437
Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. 61
21992404 2012
438
Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. 61
24009409 2012
439
Progress in gene therapy for prostate cancer. 61
23181221 2012
440
Botulinum toxin A in prostate disease: a venom from bench to bed-side. 61
22409179 2012
441
Estrogen receptor β activation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations. 61
22808245 2012
442
Preventing Unnecessary Invasive Cancer-Diagnostic Tests: Changing the Cut-off Points. 61
23113134 2012
443
Dioxin (TCDD) induces epigenetic transgenerational inheritance of adult onset disease and sperm epimutations. 61
23049995 2012
444
Chronic prostatic infection and inflammation by Propionibacterium acnes in a rat prostate infection model. 61
23240022 2012
445
[Relations between red cell structure, function and immune homeostasis in prostatic diseases]. 61
22646001 2012
446
Prostate disease risk factors among a New Zealand cohort. 61
23363810 2012
447
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease? 61
22848218 2012
448
Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database. 61
21826727 2012
449
The Correlation between Diffusion-Weighted Imaging and Histopathological Evaluation of 356 Prostate Biopsy Sites in Patients with Prostatic Diseases. 61
22792487 2012
450
Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ. 61
22347418 2012
451
Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. 61
22514625 2012
452
Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases. 61
21907698 2011
453
Adjuvant radiotherapy following radical prostatectomy for prostate cancer. 61
22161411 2011
454
What is the likelihood of requiring contralateral inguinal hernia repair after unilateral repair? 61
22000721 2011
455
In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay. 61
22019475 2011
456
Cholesterol and benign prostate disease. 61
21862201 2011
457
The functional role of reactive stroma in benign prostatic hyperplasia. 61
21664759 2011
458
Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. 61
22054323 2011
459
Examining risk perception among men with a family history of prostate cancer. 61
21310580 2011
460
Kappa statistics in the screening of malignancy of prostate. 61
22666930 2011
461
Controversies in using urine samples for Prostate Cancer detection: PSA and PCA3 expression analysis. 61
22234006 2011
462
Role of glutathione-S-transferase P1 hypermethylation in molecular detection of prostate cancer. 61
21631298 2011
463
Estrogenic environmental chemicals and drugs: mechanisms for effects on the developing male urogenital system. 61
21827855 2011
464
Smooth muscle cell-specific knockout of androgen receptor: a new model for prostatic disease. 61
21733831 2011
465
Detecting gene-gene interactions in prostate disease in African American men. 61
21992608 2011
466
Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men. 61
21382022 2011
467
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. 61
21091976 2011
468
An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. 61
21656824 2011
469
Inflammation and benign prostatic hyperplasia: clinical implications. 61
21519898 2011
470
The complex interplay between cholesterol and prostate malignancy. 61
21798387 2011
471
Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. 61
21684555 2011
472
Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism. 61
21624358 2011
473
Factors influencing quality of life after total laryngectomy: a study of 92 patients. 61
21845804 2011
474
Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion molecules. 61
21489806 2011
475
The effects and prospects of the integration of traditional Chinese medicine and Western medicine on andrology in China. 61
21642998 2011
476
Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. 61
21557269 2011
477
Towards the prevention and management of prostatic diseases in Nigeria: a framework. 61
22135603 2011
478
Prostate diseases in Lagos, Nigeria: a histologic study with tPSA correlation. 61
21670775 2011
479
Bicycle riding: impact on lower urinary tract symptoms and erectile function in healthy men. 61
21811700 2011
480
The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator. 61
21147815 2011
481
Prostatic disease and sexual dysfunction. 61
21750746 2011
482
Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options. 61
26579287 2011
483
Increased levels of plasma haemoxygenase-1 in prostate cancer. 61
21263452 2011
484
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆). 61
21554885 2011
485
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. 61
20883781 2011
486
Estrogen action and prostate cancer. 61
21765856 2011
487
Precedence for prostate brachytherapy. 61
20729153 2011
488
[proPSA: a precursor of prostate-specific antigen, may improve the early diagnosis of prostate cancer]. 61
21678645 2011
489
[The role of functional condition of pelvic inferior muscles and corticospinal tract in urination disorders in prostatic diseases]. 61
21870479 2011
490
Is testosterone a friend or a foe of the prostate? 61
21457469 2011
491
Association of Mycoplasma hominis infection with prostate cancer. 61
21471611 2011
492
Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system. 61
21040364 2011
493
Prostate diseases--role of sex steroids and their inhibitors. 61
21397203 2011
494
The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. 61
19762255 2011
495
Pharmacological characterization of zinc and copper interaction with the human alpha(1A)-adrenoceptor. 61
21262225 2011
496
Selective nanoparticle-directed ablation of the canine prostate. 61
21412805 2011
497
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. 61
20632317 2011
498
Association of black race with follow-up of an abnormal prostate-specific antigen test. 61
21443067 2011
499
High-fat diet increases NF-κB signaling in the prostate of reporter mice. 61
20632379 2011
500
The lady with raised prostate specific antigen: do we need to worry? 61
22292649 2011
501
Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort. 61
22096650 2011
502
Role of inflammation in benign prostatic hyperplasia. 61
22110398 2011
503
Recent role of inflammation in prostate diseases: chemoprevention development opportunity. 61
21339547 2011
504
Effects of aging and ethnicity on serum free prostate specific antigen. 61
22320948 2011
505
Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. 61
21074211 2011
506
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. 61
21126868 2011
507
NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. 61
19771394 2010
508
Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. 61
20575982 2010
509
Prostate Cancer and Prostatic Diseases. Editor's comments. 61
21068743 2010
510
Early-life estrogens and prostate cancer in an animal model. 61
24795802 2010
511
[Distribution and significance of α1-adrenoceptor subtypes in patients with chronic prostatitis in prostate, bladder detrusor and posterior urethral tissue]. 61
21223784 2010
512
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. 61
21151972 2010
513
Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. 61
21079217 2010
514
Prostate cancer screening perspective, Malaysia. 61
21062649 2010
515
The novel prostate cancer antigen 3 (PCA3) biomarker. 61
21176272 2010
516
Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database. 61
20679895 2010
517
Intrinsic fluorescence of protoporphyrin IX from blood samples can yield information on the growth of prostate tumours. 61
20419341 2010
518
The effectiveness of dried cranberries ( Vaccinium macrocarpon) in men with lower urinary tract symptoms. 61
20804630 2010
519
Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways. 61
20941365 2010
520
Epigenetic transgenerational actions of vinclozolin on promoter regions of the sperm epigenome. 61
20927350 2010
521
Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. 61
20647404 2010
522
Prevalence of urinary incontinence in men, women, and children--current evidence: findings of the Fourth International Consultation on Incontinence. 61
20541241 2010
523
Long-term Safety of Testosterone and Growth Hormone Supplementation: A Retrospective Study of Metabolic, Cardiovascular, and Oncologic Outcomes. 61
21629532 2010
524
[Study on interpretation of quantitative results of prostate-specific antigen using information theory]. 61
20805707 2010
525
1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells. 61
20606040 2010
526
Effect of lycopene on androgen receptor and prostate-specific antigen velocity. 61
20819671 2010
527
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. 61
20514437 2010
528
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. 61
20535861 2010
529
[Bacterial 16S rRNA genes and expression of IL-1β, TNF-α and IgA in prostate tissues]. 61
20979861 2010
530
Differential expression of genes in co-cultured versus separately cultured fibroblasts and epithelial cells from human benign hyperplastic prostate tissues. 61
20514417 2010
531
[Identification of Mycoplasma in patients with suspected prostate cancer]. 61
20799402 2010
532
Effect of anthropometric measurements and personal data parameters on benign prostatic hyperplasia and carcinoma prostate. 61
22338417 2010
533
Polymorphisms in Toll-like receptor genes--implications for prostate cancer development. 61
20698170 2010
534
Comment on basal epithelial stem cells as efficient targets for prostate cancer initiation. 61
20529385 2010
535
Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. 61
20510305 2010
536
Prostatic diseases in the senescence: structural and proliferative features. 61
20187843 2010
537
Small-cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model? 61
20023690 2010
538
Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. 61
20102753 2010
539
ACR appropriateness criteria on obstructive voiding symptoms secondary to prostate disease. 61
20362939 2010
540
Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease. 61
21209527 2010
541
Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis. 61
19728168 2010
542
Androgens and male aging: Current evidence of safety and efficacy. 61
20154699 2010
543
Human benign prostatic hyperplasia heterotransplants as an experimental model. 61
19946317 2010
544
Hormonal influences in prostate cancer: an update of a complex subject. 61
23965417 2010
545
Effects of a prostate awareness pilot on GP consultations and PSA requests. 61
19942689 2010
546
Aromatase and regulating the estrogen:androgen ratio in the prostate gland. 61
19896534 2010
547
Determinants of male reproductive health disorders: the Men in Australia Telephone Survey (MATeS). 61
20181284 2010
548
Diagnosing urological disorders in ageing men. 61
20307027 2010
549
Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells. 61
20140087 2010
550
[Expressions of bacterial 16S rRNA, IL-1beta, TNF-alpha and NGF in prostate tissues]. 61
20180403 2010
551
Exploring older peoples' experiences of nocturia: a poorly recognised urinary condition that limits participation. 61
20302443 2010
552
The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction. 61
19912506 2010
553
[Prevalence of erectile dysfunction in patients consulting urological clinics: the ENJEU survey (one day national survey on prevalence of male sexual dysfunction among men consulting urologists)]. 61
19945668 2009
554
Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. 54
19541477 2009
555
Clinicopathological behavior of single focus prostate adenocarcinoma. 61
19836800 2009
556
Effect of spinal cord injury upon prostate: adenocarcinoma of prostate in a spinal cord injury patient - a case report. 61
20062548 2009
557
Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. 61
19375269 2009
558
Classification of prostatic diseases by means of multivariate analysis on in vivo proton MRSI and DCE-MRI data. 61
19579258 2009
559
The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients. 61
19882057 2009
560
An acute urinary retention in an old man caused by a giant Müllerian duct cyst: a case report. 61
19946447 2009
561
The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer. 61
19426190 2009
562
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. 61
19825806 2009
563
United States military contributions to the National Cancer Institute. 61
19720303 2009
564
[Optimisation of early diagnosis of prostatic diseases in megapolis setting]. 61
20213912 2009
565
Epigenetic transgenerational effects of endocrine disruptors on male reproduction. 61
19711250 2009
566
The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. 61
19720304 2009
567
Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. 54
19375853 2009
568
Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. 61
19792969 2009
569
Cadmium concentration and metallothionein expression in prostate cancer and benign prostatic hyperplasia of humans. 61
19586829 2009
570
Dietary patterns, supplement use, and the risk of benign prostatic hyperplasia. 61
19570489 2009
571
Mitochondrial haplogroups and control region polymorphisms are not associated with prostate cancer in Middle European Caucasians. 61
19636411 2009
572
Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. 61
18280636 2009
573
Clinical guidelines: should 5 alpha-reductase inhibitors be used for prostate disease? 61
19578352 2009
574
Prostatic perfusion in the dog using contrast-enhanced Doppler ultrasound. 61
19754598 2009
575
[Chronic prostatitis and biofilm]. 61
19696557 2009
576
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. 61
19267353 2009
577
The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? 61
19543428 2009
578
Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. 61
19436293 2009
579
Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells. 61
19199789 2009
580
Role of the renin-angiotensin system in prostate cancer. 61
18824067 2009
581
Dystroglycan patterns on the prostate of non-obese diabetic mice submitted to glycaemic control. 61
19335554 2009
582
High-fat diet, obesity and prostate disease: the ATX-LPA axis? 61
19204739 2009
583
A new vision for the study of benign prostate disease: the NIDDK Prostate Research Strategic Plan. 61
19150562 2009
584
Testosterone deficiency syndrome: treatment and cancer risk. 61
19429438 2009
585
Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. 61
19252750 2009
586
The dual, opposing roles of estrogen in the prostate. 61
19250203 2009
587
AHR signaling in prostate growth, morphogenesis, and disease. 61
18977204 2009
588
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. 61
19228530 2009
589
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. 61
18942119 2009
590
Prostate Cancer and Prostatic Diseases. Report from Durham. 61
19204722 2009
591
Incidence of inguinal hernia after prostate surgery: open radical retropubic prostatectomy versus open simple prostatectomy versus transurethral resection of the prostate. 61
19120532 2009
592
Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions. 61
19440015 2009
593
Perspective of Botox for treatment of male lower urinary tract symptoms. 61
19057212 2009
594
Saw palmetto extract induces nuclear heterogeneity in mice. 61
21783933 2009
595
Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer. 54
19152248 2009
596
[Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]. 61
19205388 2008
597
Developing instruments to measure the quality of decisions: early results for a set of symptom-driven decisions. 61
18718734 2008
598
Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia. 61
19149228 2008
599
Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods. 54
18579171 2008
600
Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. 61
19512848 2008
601
Androgen receptor CAG repeat polymorphisms in canine prostate cancer. 61
18783352 2008
602
[Complications using the laser]. 61
19140597 2008
603
Participation of caudal müllerian mesenchyma in prostate development. 61
18801537 2008
604
Enhancement characteristics of benign and malignant focal peripheral nodules in the peripheral zone of the prostate gland studied using contrast-enhanced transrectal ultrasound. 61
18774354 2008
605
Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. 54
18820278 2008
606
Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men. 61
18843748 2008
607
Inhibition of prostate efferent neurotransmission by amikacin. 61
18512731 2008
608
[Efficacy of vitaprost forte in patients with prostatic adenoma]. 61
19069497 2008
609
Minireview: regulation of prostatic stem cells by stromal niche in health and disease. 61
18535102 2008
610
A novel splice variant of the nuclear coactivator p120 functions strongly for androgen receptor: characteristic expression in prostate disease. 61
18560202 2008
611
Educating patients about lifestyle modifications for prostate health. 61
18675616 2008
612
Lignans isolated from Campylotropis hirtella (Franch.) Schindl. decreased prostate specific antigen and androgen receptor expression in LNCaP cells. 61
18656936 2008
613
Androgen deprivation by activating the liver X receptor. 61
18450964 2008
614
Differential proteomics in the aging Noble rat ventral prostate. 61
18546156 2008
615
Prostate development: a historical perspective. 61
18462432 2008
616
Gene expression profiling in the developing prostate. 61
18462436 2008
617
Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. 61
18403105 2008
618
Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA. 61
18489403 2008
619
Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. 61
18302221 2008
620
[Official statistics on urological morbidity in the Russian Federation]. 61
18672498 2008
621
Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. 61
18497498 2008
622
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. 61
18405753 2008
623
Prostate stem cells: the niche and cell markers. 61
18380813 2008
624
Circulating PSA-containing macrophages as a possible target for the detection of prostate cancer: a three-color/five-parameter flow cytometric study on peripheral blood samples. 61
18343793 2008
625
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. 61
18471794 2008
626
Transgenerational effects of the endocrine disruptor vinclozolin on the prostate transcriptome and adult onset disease. 61
18220299 2008
627
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. 61
18280514 2008
628
Biomarkers for early prostate cancer detection. 61
18427435 2008
629
The role of estrogens and estrogen receptors in normal prostate growth and disease. 61
18093629 2008
630
Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. 61
18207193 2008
631
[Prostatic diseases in elderly men: contemporary diagnosis and treatment of cancer and benign hyperplasia of the prostate]. 61
18441479 2008
632
The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men. 61
17850358 2008
633
Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. 61
18194690 2008
634
Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. 61
18226066 2008
635
[Results of German "Men's Health Awareness Days" in 2006]. 61
18231772 2008
636
[Analysis of the results of percent free prostate specific antigen detection among the men without prostate diseases in Xi'an]. 61
18250060 2008
637
Correlates of urinary, fecal, and dual incontinence in older African-American and white men and women. 61
18070007 2008
638
The intercellular adhesion molecule, cadherin-10, is a marker for human prostate luminal epithelial cells that is not expressed in prostate cancer. 61
18084254 2008
639
PROBE: patient and physician behaviour and education in prostate disease. 61
18173808 2008
640
Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. 61
17803183 2008
641
The use of botulinum neurotoxin type A (BoNTA) in urology. 61
18322639 2008
642
Epigenetic programming of the germ line: effects of endocrine disruptors on the development of transgenerational disease. 61
18252044 2008
643
Testosterone for the aging male; current evidence and recommended practice. 61
18488876 2008
644
Testosterone levels in benign prostatic hypertrophy and prostate cancer. 61
18362481 2008
645
HLA class II antigen presentation by prostate cancer cells. 61
17938645 2008
646
Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats. 61
18379994 2008
647
Training in male sexual and reproductive health for a primary care physician. 61
25606115 2008
648
Nutraceuticals in Prostate Disease: The Urologist's Role. 61
18836556 2008
649
Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer? 61
17907049 2008
650
Analysis of iron, zinc, selenium and cadmium in paraffin-embedded prostate tissue specimens using inductively coupled plasma mass-spectrometry. 61
19013358 2008
651
Metabolic syndrome in sub-Saharan Africa: "smaller twin" of a region's prostatic diseases? 61
18288584 2008
652
[Curcumin in the treatment of prostatic diseases]. 61
18297817 2008
653
[Capacities of complex ultrasound study in the diagnosis of prostate cancer]. 61
22187902 2008
654
Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study. 54
17997422 2008
655
Prevention of urinary and fecal incontinence in adults. 61
18457475 2007
656
Peripheral zone hypoechoic lesions of the prostate: evaluation with contrast-enhanced gray scale transrectal ultrasonography. 61
18029918 2007
657
An assessment of the virtual conversations method for prostate cancer patient education. 61
18217532 2007
658
Surgical management of common canine prostatic conditions. 61
18210976 2007
659
[Efficacy and safety of a new dosage form of vitaprost (tablets coated with intestinally soluble cover) in patients with prostatic adenoma]. 61
18649662 2007
660
Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. 61
17886252 2007
661
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. 61